Cell systems
Studies can test inflammatory signalling, transport and cellular responses under controlled laboratory conditions.
Evidence profile · O-005
KPV: gut and inflammation claims
Cell and mouse findings are not human treatment evidence. KPV has a preclinical anti-inflammatory literature, but no dependable controlled human outcomes or established human exposure profile.
KPV is not supported by controlled human evidence for gut disease, inflammation, wound healing or general “immune support”. Published findings come mainly from cell systems and animal models. In its 2026 compounding review, the FDA reported that it had not identified clinical studies or human exposure data for KPV drug products.
KPV is a lysine-proline-valine tripeptide associated with the carboxyl-terminal sequence of alpha-melanocyte-stimulating hormone. A pathway effect in cultured cells or a mouse colitis model can justify research; it cannot establish a clinical benefit, human safety profile or the quality of a consumer product.
Evidence ladder
What each research layer can answer
Animal models
Mouse colitis or wound models can test biological activity in a whole organism with a constructed disease state.
Human exposure
Pharmacokinetics and monitored safety would show what happens after a defined human product and route.
Clinical outcomes
Controlled trials would need to show patient-important benefit in a defined condition. KPV has not reached this evidential layer.
Preclinical findings
Why the gut hypothesis remains a hypothesis
Studies have reported anti-inflammatory effects in intestinal cell systems and mouse colitis models. These findings support research into melanocortin-related pathways and possible peptide transport. They do not tell us whether KPV improves symptoms, endoscopic disease, relapse, hospitalisation or quality of life in people.
Animal models simplify and provoke aspects of disease. Human inflammatory bowel disease has varied causes, medicines, microbiota and clinical courses. Translation requires a defined formulation, dose-finding, safety work and controlled clinical outcomes.
Current review
What the 2026 FDA assessment adds
| Question | FDA finding | Interpretation |
|---|---|---|
| Human effectiveness | No clinical studies identified | No basis for a clinical benefit estimate |
| Human exposure | No human exposure data identified for KPV drug products | Human safety frequency cannot be inferred |
| Substance identity | Free base and acetate are distinct bulk drug substances | The short name “KPV” may hide a material distinction |
| 503A list recommendation | FDA’s criteria weighed against inclusion | This is a US compounding-policy assessment, not a UK product test |
Product boundary
Unknown human safety and unknown vial quality are separate gaps
Even a future clinical signal would apply only to the tested material, route and product controls. A separate vial needs batch-specific identity and quantity evidence, plus methods for peptide-related impurities, aggregation, sterility, endotoxin and particulates where relevant.
“No adverse events reported” has little meaning when human exposure counts, product identity and surveillance are missing. It cannot be converted into “safe”.
A credible first-in-human programme would usually establish a characterised drug product, justify starting exposure from nonclinical work, monitor pharmacokinetics and prespecify stopping rules. Later trials would need a defined disease, suitable comparator and patient-important outcomes. None of those steps can be replaced by sales volume, testimonials or repeat laboratory findings in the same animal model.
EffectivenessNo human clinical study identified
ExposureNo human data identified
IdentityFree base versus acetate
ProductBatch-specific evidence needed
Decision boundary
What remains unknown
A future result in one inflammatory condition would not create a general “gut support” conclusion. Ulcerative colitis, Crohn’s disease, irritable bowel syndrome, infection and wound healing involve different populations, endpoints and comparators. The first useful human studies would need to name the condition and product precisely.
- Whether KPV produces any clinically important benefit in a defined human condition.
- How KPV is absorbed, distributed, metabolised and cleared in people.
- The frequency and severity of short-term or delayed harms.
- Whether free-base and acetate products behave differently.
- Whether a particular vial contains the named substance at the stated amount.
- Whether product impurities, aggregation, sterility, endotoxin and stability are controlled.
Evidence ledger
Sources and limits
These sources define the conclusions on this page. A citation supports only the proposition stated beside it.
| Source | What it establishes | What it does not establish | Checked |
|---|---|---|---|
| FDA: 2026 KPV compounding review | FDA found no clinical studies or human exposure data and assessed free base and acetate separately. | The briefing does not test an individual UK product or make a final UK decision. | |
| PubMed: KPV in experimental colitis | A preclinical study reported activity in mouse colitis models. | A mouse model does not establish treatment benefit or safety in people. | |
| PubMed: PepT1 and KPV intestinal research | Cell and animal work examined intestinal transport and inflammatory pathways. | It is not a controlled human treatment trial. | |
| PubMed: KPV in human keratinocytes | Cultured human cells showed a laboratory anti-inflammatory signal. | Human cells in culture are not human exposure or clinical evidence. | |
| FDA: bulk-substance safety risks | FDA states that no human exposure data were identified and important safety information is lacking. | It does not show that every product causes a specific harm. |
Continue the investigation
Read the connected evidence
- the gut and inflammation claims assessedCompare KPV with BPC-157, LL-37 and thymosin alpha-1 at the correct evidence layer.
- how we assess preclinical evidenceSee why mechanism and animal results cannot supply a human verdict.
- known versus unknown risksKeep observed harms separate from an unmeasured safety profile.
- what tests can proveReview batch-specific identity and microbiological evidence.
Quick answers
Frequently asked questions
Does KPV heal the gut?
No controlled human evidence establishes gut healing, symptom improvement or disease modification. The published rationale is preclinical.
Has KPV been tested in people?
The FDA’s 2026 assessment reported that it identified no clinical studies or human exposure data for KPV drug products.
Do studies in human cells count as human evidence?
They count as laboratory evidence using human-derived cells, not as human exposure or a clinical trial.
Is KPV authorised in the UK?
No UK marketing authorisation was identified under the KPV name. Check the current MHRA database for the exact product.
Does the absence of reported harm mean KPV is safe?
No. Without dependable human exposure and surveillance, the frequency and severity of harms remain unknown.
What remains unknown?
Human benefit, pharmacology, safety frequency and the identity and quality of individual KPV products remain unresolved.
Evidence library
Claim-level evidence records
Open the individual records behind this profile. Each record links to the primary and official sources used for its verdict.
Profile-to-record links checked 10 August 2026. These evidence records received named scientific and clinical sign-off on 10 August 2026.
Editorial experience
From our work: how we checked this page
For topical-map item O-005, KPV evidence: gut and inflammation claims was checked as a distinct editorial task, not treated as a generic peptide page. We reviewed 5 unique external sources and 8 internal destinations in the page, then checked that the opening answer, headings, source descriptions and linked next steps stayed within the same claim boundary. The count records links in the published page and is not a claim that every source carries equal evidential weight.
Eleni Kiromitis checked study design, biomedical evidence, evidence directness and laboratory context. Dr Stavroula Nikitopoulou checked clinical claims, adverse effects, contraindications, red flags and patient-facing safety wording. Each reviewer stayed within the remit published on the governance page. Yianni Kiromitis retained responsibility for source verification, editorial decisions and correction management.
We did not use patient experience, a personal treatment outcome, seller testimony or an assumed product identity to support this page. The publication did not independently test a vial for this review. Where a page refers to a laboratory result, that result applies only to the named sample, method and attribute. We kept uncertainty beside the conclusion, recorded which source supports each material claim, and checked that the visible review date matches the publication record. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.